PARP Inhibitor Olaparib Use in a BRCA1-Positive Patient With Metastatic Triple-Negative Breast Cancer, Without the Initial Use of Platinum-Based Chemotherapy, Showing Significant Rapid Near Resolution of Large Liver Metastasis While Patient Experienced Gout-Like Symptoms:

Trevanne Matthews-Hew,Lara Zuberi

PARP Inhibitor Olaparib Use in a BRCA1-Positive Patient With Metastatic Triple-Negative Breast Cancer, Without the Initial Use of Platinum-Based Chemotherapy, Showing Significant Rapid Near Resolution of Large Liver Metastasis While Patient Experienced Gout-Like Symptoms:

2019

Trevanne Matthews-Hew
Lara Zuberi

Triple-negative breast cancer (TNBC) accounts for 20% of breast cancers diagnosed worldwide. This subtype of breast cancer tends to behave more aggressively, and unlike other breast cancer subtypes...

Keywords:

Breast cancer
Gout
Oncology
PARP inhibitor
Olaparib
Metastasis
Triple-negative breast cancer
Medicine
Internal medicine
Chemotherapy
positive patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations